Metoprololtartrat Al (Metoprolol Tartrate Ph. Eur.)

Metoprolol tartrate selectively antagonises β1‑adrenergic receptors in cardiac tissue. By blocking these receptors, it reduces sympathetic stimulation, leading to a slower heart rate, decreased myocardial contractility, and lower cardiac output, which together lower arterial pressure and myocardial oxygen demand.

The appropriate dose of Metoprololtartrat Al is determined by a qualified prescriber based on the patient’s clinical condition, response to therapy, and any comorbidities. Dosage may be adjusted during treatment to achieve optimal blood pressure or heart‑rate control.

Data on the safety of metoprolol tartrate in pregnancy and lactation are limited. It is generally classified as a drug to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Metoprolol is a cardio‑selective (β1‑selective) beta blocker, offering a lower risk of bronchospasm compared with non‑selective agents such as propranolol. It is commonly preferred for patients with respiratory disease who still require beta‑blockade. Its pharmacokinetic profile allows once‑ or twice‑daily dosing, whereas some alternatives may require more frequent administration.

Store Metoprololtartrat Al at temperatures below 25 °C, in the original packaging, and protect it from moisture and direct sunlight. Do not store in a location where temperature may exceed the recommended range, as this could affect product stability.

Metoprololtartrat Al is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water. The exact timing (e.g., morning or evening) and frequency depend on the individual treatment plan.

Serious adverse events include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with asthma or COPD, and allergic reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience fainting, chest pain, severe shortness of breath, or signs of an allergic reaction.

Metoprololtartrat Al is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, and uncontrolled heart failure. Caution is also advised for individuals with severe asthma, chronic obstructive pulmonary disease, or significant peripheral vascular disease.